Pyramid Analytics Ascends to the Large / Enterprise-Wide Implementations Category in BARC BI & Analytics 22 Report
11.11.2021 16:00:00 EET | Business Wire | Press release
Pyramid Analytics announced today that BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category. Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (place top 22-33% or top 2 products in its 6 peer groups) in The BI & Analytics Survey 22. Based on a sample of 2,478 survey responses, the BARC report offers an unsurpassed level of user feedback on 30 leading business intelligence (BI) solutions. BARC is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence and analytics (ABI).
Key Points:
- 100 percent of customers surveyed would recommend Pyramid Analytics.
- 97 percent of users rate Pyramid’s functionality for creating dashboards as excellent or good, beating the average rating by 82 percent.
- 91 percent of users rate Pyramid Analytics’ vendor support as excellent or good. This is in sharp contrast with just 65 percent for the average BI tool.
- 88 percent of users rate Pyramid Analytics’ price to value as excellent or good; notably higher than the 71 percent for average tools.
- Download the complimentary report.
BARC Net Assessment
“It has been another great year for Pyramid Analytics, scoring 40 top ranks and 87 leading positions across its six peer groups. Pyramid performed especially well in comparison to its rivals in the Large/Enterprise-Wide Implementations peer group, where half of its top ranks came,” the report’s authors wrote, adding that “Pyramid customers clearly benefit from using the software. We asked customers to rate their level of achievement of 11 different business benefits. Pyramid scored well above average in almost all these benefits. Compared to other vendors in the survey, Pyramid customers are especially likely to be able to reduce costs, improve customer satisfaction, and improve operational efficiency.”
BARC determined that the Pyramid Analytics Decision Intelligence Platform deployments, use cases, functionality, and performance met its requirements for Enterprise-Wide Implementations; is well-suited to support a broad range of BI and analytics use cases and large numbers of end-users in multiple roles; and is capable of managing Big Data without compromising critical factors such as query response time, flexible self-service, and ease of use.
Complete, Integrated Decision Intelligence
Only Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use disparate, multiple tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, and industry-leading user adoption means faster time to value.
The Pyramid Analytics Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps from Original Equipment Manufacturers (OEM) and Independent Software Vendors (ISV) or delivered through Managed Services Providers (MSP).
Voice of the Customer
- “A powerful platform with an abundance of well-thought out, integrated features and functionality. Fast, modern and sophisticated without being complicated.” Head of BI & Analytics Competence Center, Retail Industry, >2,500 employees
- “A polished product supported by an enthusiastic and knowledgeable team.” CIO, Energy Industry, >2,500 employees
- “A great product. Flexible and excellent self-service [BI & Analytics].” BI/Analytics Leader, Manufacturing Industry, >2,500 employees
Quotes
- Carsten Bange, Founder and CEO, BARC: “If you are considering buying a BI product, you really need to know how other users and organizations rate it. The BI & Analytics Survey 22 captures what end users really think about the BI products they use. Input from Pyramid Analytics customers and our own assessment of its ABI platform revealed continued innovation. Pyramid Analytics is a growing vendor with an increasing presence in the market. Its product is highly competitive, as the results in The BI & Analytics Survey 22 show. It is therefore unsurprising to see it has a high win rate when competing for new deals. I am eager to watch their progress over the next year.”
- Omri Kohl, CEO & Co-Founder, Pyramid Analytics: “We place tremendous value on The BI & Analytics Survey because BARC provides a painstakingly thorough analysis and, importantly, draws from real-world, hands-on experience. I thank Carsten and his team for their diligent research. And I am proud that the Pyramid Analytics Decision Intelligence Platform is again top-ranked or in a leadership position in all categories that mean the most to enterprise customers.”
Download a complimentary copy of Pyramid highlights in The BI & Analytics Survey 22 from BARC now.
About The BI & Analytics Survey 22
The BI & Analytics Survey 22 was conducted by BARC from March to June 2021. Altogether, 2,487 respondents worldwide answered a series of questions about their BI and analytics software. The survey offers a comparison of 30 leading business intelligence tools across 36 key performance indicators including Business Value, Customer Satisfaction, Customer Experience and Competitiveness. For more information, go to www.bi-survey.com.
About Pyramid Analytics
The Decision Intelligence Platform from Pyramid Analytics enables enterprises in any industry to maximize the value of data by unifying Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) infrastructure. By balancing performance and ease of use, everyone from business users to the most advanced data scientists get real-time, direct self-service access to reliable data from any domain or source, customized reports, and clear, actionable analysis. Flexible deployment options include on-premises and multi-cloud and hybrid environments. Schedule a demo.
Pyramid Analytics has offices in global innovation and business centers, including Amsterdam, London, New York City (US HQ), and Tel-Aviv, Israel. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
The Pyramid Decision Intelligence Platform. Know What’s Next.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005534/en/
Contact information
Chas Kielt
Vice President of Corporate Communications | Product and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom